Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics Raises $7M

NEW YORK (GenomeWeb News) – Exosome Diagnostics has raised $7 million toward a goal of $8.5 million, it said in a regulatory filing on Thursday.

In an amended Form D filed with the US Securities and Exchange Commission, the New York-based molecular diagnostic firm said that the types of securities offered were in the form of debt; option, warrant, or other right to acquire another security; and security toe be acquired upon exercise of option, warrant, or other right to acquire security.

It did not identify the investors in the financing or how the proceeds would be used. Company officials did not respond to a request for comment.

In June, the company said in an SEC document that it raised $6.5 million toward a targeted $8 million raise, and in February, it said in another regulatory filing that it raised $5 million toward a $6 million round. It is unclear if the raise disclosed this week is related to the prior two financing rounds.

Exosome raised $20 million in 2010.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.